Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Short-term Investments (2017 - 2025)

Historic Short-term Investments for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $593.0 million.

  • Arcus Biosciences' Short-term Investments fell 3322.07% to $593.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $593.0 million, marking a year-over-year decrease of 3322.07%. This contributed to the annual value of $828.0 million for FY2024, which is 3101.27% up from last year.
  • As of Q3 2025, Arcus Biosciences' Short-term Investments stood at $593.0 million, which was down 3322.07% from $663.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Short-term Investments registered a high of $900.1 million during Q2 2022, and its lowest value of $345.2 million during Q3 2021.
  • Over the past 5 years, Arcus Biosciences' median Short-term Investments value was $700.0 million (recorded in 2023), while the average stood at $673.4 million.
  • Data for Arcus Biosciences' Short-term Investments shows a peak YoY increase of 38229.07% (in 2021) and a maximum YoY decrease of 3841.95% (in 2021) over the last 5 years.
  • Over the past 5 years, Arcus Biosciences' Short-term Investments (Quarter) stood at $351.0 million in 2021, then skyrocketed by 128.77% to $803.0 million in 2022, then fell by 21.3% to $632.0 million in 2023, then surged by 31.01% to $828.0 million in 2024, then fell by 28.38% to $593.0 million in 2025.
  • Its Short-term Investments was $593.0 million in Q3 2025, compared to $663.0 million in Q2 2025 and $805.0 million in Q1 2025.